RJ Hamster
“Golden Dawn”: The Code Name That Should Be on…
Editor’s Note: Our friend Louis Navellier has been a guest at Mar-a-Lago more than 10 times and manages a $1.1 billion portfolio – including $358 million in AI stocks. He called Nvidia before it went up 44,000%, Apple before it went up 36,000%, and Microsoft before its 60,800% rise. Now he says Trump’s new AI project – which just received its official code name – represents the biggest investment event of his 40-year career.
Dear Reader,
When a little known government project gets a name…
It means we’re closer to a major breakthrough than most people think.
And for investors who get ahead of it, that timing could mean everything.
The name is “Golden Dawn.”
That’s what President Trump’s team is calling America’s new Manhattan Project – but for AI.
Right now, behind the razor wire of a secretive government lab in the mountains of Tennessee…
Spanning a territory larger than the state of Texas…
Built to accelerate AI breakthroughs by 36,000%.
One government insider working on the project called it “a scientific instrument for the ages.”
And when Golden Dawn goes live, it will instantly leapfrog every AI model on earth – ChatGPT, Gemini, and Elon’s Grok – in a single stroke.
The financial implications are staggering.
Certain AI stocks will be rendered obsolete overnight…
While sending shares of one specific company – the one I’ve been quietly tracking for months – soaring.
I’ve laid out the full case in a new presentation – including why you need to act before May 5th.
I even name the company down to the ticker.
Click here to watch it now, free of charge.
Regards,
Louis Navellier
Senior Quantitative Investment Analyst, InvestorPlace
P.S. “Golden Dawn” will span more than 700 miles – making it by far the largest AI infrastructure project ever built. When Trump flips the on switch, I believe it will trigger a $100 trillion reset of the AI markets. I’m revealing the one stock at the center of it all. Go here for the details.
FEATURED ARTICLE
The Longevity Economy Just Produced Its Most Compelling Stock Setup in Years
The weight loss drug revolution did not end with Ozempic. That was merely the opening act.
The GLP-1 wave that swept through pharmaceutical markets over the past two years has done something far more significant than generate blockbuster revenues for Novo Nordisk and Eli Lilly. It has fundamentally rewired how Wall Street thinks about metabolic disease, longevity science, and the multi-trillion-dollar healthcare cost burden tied to obesity, type 2 diabetes, and cardiovascular risk.
And in the wake of that rewiring, a second and third generation of metabolic health companies is emerging – with more targeted mechanisms, fewer side effects, and significantly larger addressable markets.
One company that has captured serious institutional attention in early 2026 is Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biotech developing oral small-molecule GLP-1 receptor agonists – essentially, a pill-form alternative to injectable weight loss drugs.
Why Oral Delivery Changes Everything
The injectable format of current GLP-1 therapies remains a meaningful adoption barrier. Patient compliance drops sharply with self-injection regimens, particularly in markets outside the U.S. with less robust specialty pharmacy infrastructure. An effective oral GLP-1 agonist would unlock a dramatically larger patient population.
Structure Therapeutics’ lead candidate, GSBR-1290, has posted Phase 2 clinical data showing statistically significant weight reduction and a tolerability profile that compares favorably to injectable alternatives in head-to-head analysis. The company has also advanced a broader pipeline targeting cardiovascular and pulmonary metabolic indications.
The Numbers Investors Are Watching
- The global obesity therapeutics market is projected to exceed $100 billion annually by 2030
- Structure Therapeutics carries a market capitalization that reflects early-stage risk – creating asymmetric upside potential if Phase 3 data maintains Phase 2 trajectory
- The company holds a cash runway that analysts have estimated extends into late 2027, reducing near-term dilution pressure
- Partnering interest from large-cap pharmaceutical players has been noted in multiple investor presentations
Calibrated Risk Awareness
Clinical-stage biotech is not for the risk-averse. Binary trial outcomes, regulatory timelines, and a competitive landscape now crowded with well-capitalized incumbents are all real considerations. Structure Therapeutics has not yet generated commercial revenue and may require additional capital raises depending on pipeline progression.
But the convergence of a massive unmet need, a mechanistically differentiated approach, and a market that is only beginning to understand the full scope of the GLP-1 opportunity makes this a company that deserves a place on every serious biotech investor’s watchlist in 2026.
The longevity economy is not a theme. It is a structural shift. And the companies building its next chapter are still early enough to matter.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investing involves risk, including the potential loss of principal. Always do your own research before making investment decisions.
IMPORTANT NOTICE AND DISCLAIMER
Investing Media Solutions, LLC (“IMS”), the owner of this website (the “Website”), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the “Publications”). The author or authors of those Publications are solely responsible for their contents. IMS has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. IMS will NOT be liable for any loss or damage caused by a reader’s reliance on information posted on the Website or contained in the Publications.
FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company’s financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications.
SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution. Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither IMS nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization.
To more fully understand our Website, please review our full disclaimer located at: https://thecheapinvestor.com/disclaimer/
At The Cheap Investor, it’s our mission to create and provide a community that helps you invest and understand stocks. When TheCheapInvestor was established, we wanted to make the community an inclusive place where investors can come to get ahead! Not just help them with daily stock picks. The Cheap Investor are provided to you for information only and should not be considered as a stock or investment advisor. The Cheap Investor may make available certain information related to trading strategies and stock prices for educational and information purposes only; any information made available should not be construed as an endorsement, recommendation, or sponsorship of any company or security. By visiting this site or using the training materials, you acknowledge and agree that any reliance upon the content or data available through The Cheap Investor is at your own sole risk. You are strongly advised to use your own judgment, research, and consult a professional advisor.
Over the years, and with thousands of followers that use our stock picks daily, we promise to always aim to get better at what we do every single day! In addition, our primary focus is on our communication with you. It’s really important to us that every time you come to us, you end up leaving with the help you came for to take your investment portfolio to new levels.
We particularly appreciate when our following provides feedback via testimonials, reviews, and comments left on our site or social media accounts. Because with that feedback, we can use it to make your next visit to our site even better than the last!
Since we put so much effort into the relationship with you, we hope that any investment in us is exactly the way you hoped it would be. Because by choosing to go with https://TheCheapInvestor.com/, it’s our promise that we provide a community you will come back to over and over again.
Now, as much as we care about making investors more successful, we also care about your privacy. TheCheapInvestor is owned and operated by TheCheapInvestor website.
We’re committed to the right to your privacy and strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website.
What Information Do We Collect?
When you visit our Web site you may provide us with two types of information: personal information you knowingly choose to disclose that is collected on an individual basis and Web site use information collected on an aggregate basis as you and others browse our Web site.
For example, you may need to provide the following information: • Name • Website URL information • Email address • Home and business phone number
In addition to providing the foregoing information, if you choose to correspond further with us through email, we may retain the content of your email messages together with your email address and our responses. We provide the same protections for these electronic communications that we employ in the maintenance of information received by mail and telephone. It also explains important information that ensures we won’t abuse the information that you provide to us in good faith. By accessing and using our website, you can trust that what you want to be kept private, will be kept private. If at any time, you would like to read our Privacy Policy and get a better understanding of your rights and liabilities under the law.
Feel free to visit our site, find the privacy policy in the footer and read it. If there is something you are concerned about or wish to get more clarity on, please let us know by contacting us at support@thecheapinvestor.com. The Privacy Policy also informs you of how to notify us to stop using your personal information. If you wish to view our official policies, please visit our website https://TheCheapInvestor.com/
At The Cheap Investor, we are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. The Cheap Investor operates the Website.
Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using https://TheCheapInvestor/, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy. If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by emailing us at support@thecheapinvestor.com. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the “unsubscribe” link located on the bottom of any marketing email. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies.
Update your email preferences or unsubscribe here
© 2026 The Cheap Investor
203 N La Salle Suite 2100
Chicago , Illinois 60601, United StatesPowered by beehiivTerms of Service
